Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zynerba Pharmaceuticals, Inc. (ZYNE)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | | | | | 100.0% | | 100.0% | 100.0% |
| Cost of goods sold | | | | | 0.0% | | 0.0% | 0.0% |
| Gross profit | | | | | 100.0% | | 100.0% | 100.0% |
| Research and development | | | | | 31680.3% | | 231512.1% | 2669.7% |
| General and administrative | | | | | 15393.9% | | 88693.1% | 1923.4% |
| EBITDA | | | | | -46858.4% | | -320434.1% | -4483.7% |
| Depreciation | | | | | 115.8% | | 1038.6% | 9.3% |
| EBIT | | | | | -46974.2% | | -321472.8% | -4493.1% |
| Pre-tax income | | | | | -46408.3% | | -322980.0% | -4490.4% |
| Income taxes | | | | | 0.0% | | -379.9% | 9.9% |
| Net income | | | | | -46408.3% | | -322600.1% | -4500.3% |
|